BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38252427)

  • 21. SWI/SNF gene variants and glioma risk and outcome.
    Amankwah EK; Thompson RC; Nabors LB; Olson JJ; Browning JE; Madden MH; Egan KM
    Cancer Epidemiol; 2013 Apr; 37(2):162-5. PubMed ID: 23276717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma: pathology, molecular mechanisms and markers.
    Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
    Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
    Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
    Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative functional genomics identifies RINT1 as a novel GBM oncogene.
    Quayle SN; Chheda MG; Shukla SA; Wiedemeyer R; Tamayo P; Dewan RW; Zhuang L; Huang-Hobbs E; Haidar S; Xiao Y; Ligon KL; Hahn WC; Chin L
    Neuro Oncol; 2012 Nov; 14(11):1325-31. PubMed ID: 23074196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
    Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
    J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
    Saadeh FS; Morsi RZ; El-Kurdi A; Nemer G; Mahfouz R; Charafeddine M; Khoury J; Najjar MW; Khoueiry P; Assi HI
    PLoS One; 2020; 15(11):e0242793. PubMed ID: 33237934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Genomic Landscape of
    Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
    Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
    Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
    Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations associated with MRI-derived volumetric features in glioblastoma.
    Gutman DA; Dunn WD; Grossmann P; Cooper LA; Holder CA; Ligon KL; Alexander BM; Aerts HJ
    Neuroradiology; 2015 Dec; 57(12):1227-37. PubMed ID: 26337765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
    Dono A; Torres J; Nunez L; Arevalo O; Rodriguez-Quinteros JC; Riascos RF; Kamali A; Tandon N; Ballester LY; Esquenazi Y
    J Neurooncol; 2024 Mar; 167(1):99-109. PubMed ID: 38351343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
    Zhang X; Katsakhyan L; LiVolsi VA; Roth JJ; Rassekh CH; Bagley SJ; Nasrallah MP
    Am J Surg Pathol; 2021 Nov; 45(11):1516-1526. PubMed ID: 34366423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome.
    Hasselblatt M; Thomas C; Federico A; Nemes K; Johann PD; Bison B; Bens S; Dahlum S; Kordes U; Redlich A; Lessel L; Pajtler KW; Mawrin C; Schüller U; Nolte K; Kramm CM; Hinz F; Sahm F; Giannini C; Penkert J; Kratz CP; Pfister SM; Siebert R; Paulus W; Kool M; Frühwald MC
    Am J Surg Pathol; 2022 Sep; 46(9):1277-1283. PubMed ID: 35446794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genomic score to predict local control among patients with brain metastases managed with radiation.
    Lamba N; Cagney DN; Catalano PJ; Kim D; Elhalawani H; Haas-Kogan DA; Wen PY; Wagle N; Aizer AA
    Neuro Oncol; 2023 Oct; 25(10):1815-1827. PubMed ID: 37260393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
    Sande CM; Chang B; Monga V; Bossler AD; Ma D
    Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.